A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-22

Study Completion Date

2024-11-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Subjects will be administered multiple doses of VK0214 in a cohort dose escalation process. A total of up to 36 subjects will be enrolled in the study, into one of three dose cohorts. For each cohort, up to 12 subjects will be randomized to receive VK0214 or placebo in a 3:1 ratio so that there will be a total of up to 9 subjects for each of the active doses and up to 3 subjects dosed with placebo in each cohort.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.

NCT03196375

Motor Neuron Disease

TERMINATED PHASE2

Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

NCT04987671

ALS

UNKNOWN PHASE1/PHASE2

Dexpramipexole Renal PK Study

NCT01424176

Amyotrophic Lateral Sclerosis Renal Insufficiency

COMPLETED PHASE1

Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)

NCT00647296

Amyotrophic Lateral Sclerosis

COMPLETED PHASE2

A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants

NCT01495260

Adrenomyeloneuropathy

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The first part of VK0214-102 will include the first 2 dose cohorts and placebo, which will be dosed in parallel (up to N=24). The first 2 doses used in these cohorts will be 20 mg QD and 40 mg QD for 28 days. A Dose Level Review Team (DLRT) meeting will be held at the end of the first 2 parallel doses.

The DLRT will review safety, tolerability, and preliminary efficacy data from cohort 1 and 2. If the data analyzed show that the first 2 doses are safe and well tolerated the DLRT may make a recommendation for proceeding to commence dosing in the third dose cohort.

Based upon outcomes in Cohorts 1 and 2, the sponsor may decide to include a third dose cohort. Before screening may be initiated in Cohort 3, data to support dosing in this cohort will be submitted to the FDA, together with the amended protocol and the dosing recommendation of the DLRT.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VK0214 Active 20mg

20mg QD

Group Type EXPERIMENTAL

VK0214

Intervention Type DRUG

API in capsule

VK0214 Active 40mg

40mg QD

Group Type EXPERIMENTAL

VK0214

Intervention Type DRUG

API in capsule

Placebo

Placebo QD

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

API in capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VK0214

API in capsule

Intervention Type DRUG

Placebo

API in capsule

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provide a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study and is willing and able to participate.
* Have diagnosis of X-linked adrenoleukodystrophy (X-ALD) by genetic testing and elevated VLCFAs.
* Present clinical features of AMN, or adrenal insufficiency.
* Subjects must be 18 years of age and older.

Exclusion Criteria

* Have the cerebral form of X-ALD, based on medical records, or based on MRI performed within the last 12 months or MRI at screening
* Have been treated with any drug targeting TRβ or with any drug being tested as therapy for X-ALD AMN form within the past 30 days before screening
* History or presence of clinically significant acute or unstable hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, diabetes, hematological or oncological that in the opinion of the investigator would pose a significant risk for the subject
* Subject has untreated primary adrenal insufficiency based on morning plasma cortisol and ACTH at screening
* Lorenzo's Oil. Currently taking Lorenzo's Oil or erucic acid containing product, or other lipid lowering agent known to effect VLCFA levels

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No